Evoke Pharma Reports First Quarter 2018 Results and Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- US stock index futures slip as high-stakes Iran, inflation tests loom
- Oil falls ahead of US announcement of new sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
Evoke Pharma (EVOK) Tops Q1 EPS by 6c
May 14, 2018 6:37 AM EDTEvoke Pharma (NASDAQ: EVOK) reported Q1 EPS of ($0.13), $0.06 better than the analyst estimate of ($0.19).
Dave Gonyer, R.Ph., President and CEO, stated, After successfully completing our comparative exposure pharmacokinetic (PK) trial late last year, we entered 2018 with a discovery of sex-based PK differences for Gimoti. With this significant finding and additional direction from the U.S. Food and Drug Administration (FDA), we are in the process of finalizing our 505(b)(2) New Drug Application (NDA) for Gimoti. The proposed indication for Gimoti is the relief of symptoms of acute and recurrent diabetic gastroparesis in... More
